Contributions
Abstract: EP1543
Type: ePoster
Abstract Category: Therapy - disease modifying - Others
Introduction: In the last decades, therapeutic options for multiple sclerosis (MS) have multiplied. Accepted immunomodulatory treatments differ in administration route, efficacy, security profile, cost and health system coverage. Taking account of these differences, the patient should be consulted about the best treatment option, but is seems that it may be not true in daily practice.
Objective: To know MS patient"s opinion about their level of participation in therapeutic decisions and to identify a predictive pattern among different variables.
Methods: An anonymous survey was performed in July 2015 with a Hispanic population with MS that participate in patient groups of the social network Facebook (closed groups Esclerosis Múltiple and Amig@s con Esclerosis Múltiple). Data obtained were age, sex, residence country, progressive or relapsing-remitting disease, current treatment, and questions about participation in treatment decisions, satisfaction with the information given by the physician, knowledge about the treatment administered, a sense of understanding by the physician regarding patient"s questions, and perception of interest by the physician. A multivariate analysis was performed in order to identify predictive variables for participation.
Results: 500 surveys were received. Average age was 40,68 (range 18 - 84), 81,6% female. Median years of disease 6 (range 0 - 42). Most frequent residency countries were Spain (244), Mexico (86) and Argentina (45). Relapsing - remitting form 64%, progressive forms 14%, clinically isolated syndrome 5%, unknown by the patient 20%. The grade of participation in therapeutic decisions was frequent in 286 (45,6%), sometimes 130 (26%) and never 74 (14,8%). Country of residence showed a statistical difference as a predictor of participation degree (p 0,0002), being better in Argentina in comparison with Spain and México, independently of age, sex, years of disease or current treatment. Multivariate analysis identified knowledge about treatment with an OR 2,67 (CI 95% 1,45 - 4,92) and perception of doctor understanding OR 2,49 (CI 95% 1,18 - 5,23) as independent variables for participation.
Conclusions: The main conditioning variable for patient participation in therapeutic decisions was the country of residence. It is more probable to participate in therapeutic decisions if the patient knows about the treatment received and senses doctor understanding.
Disclosure:
Andres Barboza: has received personal compensation from Novartis, Biogen, Genzyme, Teva and Bayer for his role as a consultant and invited speaker.
Galeno Rojas: nothing to disclosure
Abstract: EP1543
Type: ePoster
Abstract Category: Therapy - disease modifying - Others
Introduction: In the last decades, therapeutic options for multiple sclerosis (MS) have multiplied. Accepted immunomodulatory treatments differ in administration route, efficacy, security profile, cost and health system coverage. Taking account of these differences, the patient should be consulted about the best treatment option, but is seems that it may be not true in daily practice.
Objective: To know MS patient"s opinion about their level of participation in therapeutic decisions and to identify a predictive pattern among different variables.
Methods: An anonymous survey was performed in July 2015 with a Hispanic population with MS that participate in patient groups of the social network Facebook (closed groups Esclerosis Múltiple and Amig@s con Esclerosis Múltiple). Data obtained were age, sex, residence country, progressive or relapsing-remitting disease, current treatment, and questions about participation in treatment decisions, satisfaction with the information given by the physician, knowledge about the treatment administered, a sense of understanding by the physician regarding patient"s questions, and perception of interest by the physician. A multivariate analysis was performed in order to identify predictive variables for participation.
Results: 500 surveys were received. Average age was 40,68 (range 18 - 84), 81,6% female. Median years of disease 6 (range 0 - 42). Most frequent residency countries were Spain (244), Mexico (86) and Argentina (45). Relapsing - remitting form 64%, progressive forms 14%, clinically isolated syndrome 5%, unknown by the patient 20%. The grade of participation in therapeutic decisions was frequent in 286 (45,6%), sometimes 130 (26%) and never 74 (14,8%). Country of residence showed a statistical difference as a predictor of participation degree (p 0,0002), being better in Argentina in comparison with Spain and México, independently of age, sex, years of disease or current treatment. Multivariate analysis identified knowledge about treatment with an OR 2,67 (CI 95% 1,45 - 4,92) and perception of doctor understanding OR 2,49 (CI 95% 1,18 - 5,23) as independent variables for participation.
Conclusions: The main conditioning variable for patient participation in therapeutic decisions was the country of residence. It is more probable to participate in therapeutic decisions if the patient knows about the treatment received and senses doctor understanding.
Disclosure:
Andres Barboza: has received personal compensation from Novartis, Biogen, Genzyme, Teva and Bayer for his role as a consultant and invited speaker.
Galeno Rojas: nothing to disclosure